Aims We compared outcomes of ST-elevation myocardial infarction (STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin (UFH) to support fibrinolysis.
Introduction
Fibrinolysis remains the leading re-perfusion strategy around the world for patients with ST-elevation myocardial infarction (STEMI). Despite several advantages, including development of fibrin-specific lytics and bolus-administered agents, the benefits of fibrinolysis are compromised when reocclusion of successfully re-perfused infarct arteries occurs. 1 The generation of thrombin via the coagulation cascade is pivotal in the formation of fibrin strands and activation of platelets at the site of a ruptured vulnerable plaque. Local production of thrombin is also paradoxically increased by the action of fibrinolytic agents. 2 Enzymatically active thrombin plays a key role in re-occlusion following successful coronary re-perfusion, providing the rationale for adjunctive anticoagulant therapy in STEMI patients undergoing fibrinolysis.
Unfractionated heparin (UFH) is an anti-coagulant that has been widely used in the treatment of STEMI for .40 years. Investigations have confirmed the benefits of UFH combined with fibrinolytic therapy. [3] [4] [5] The addition of UFH to fibrinolysis with streptokinase (SK) has been demonstrated to reduce death and reinfarction, 3 whereas in combination with fibrin-specific agents UFH is believed to help achieve and maintain coronary arterial patency. 4, 5 Low-molecular-weight heparins, such as enoxaparin, are an attractive potential replacement for UFH because of the convenient subcutaneous route of administration and reliable anticoagulation effects, eliminating the need for therapeutic monitoring.
The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25 (ExTRACT-TIMI 25) trial demonstrated that a strategy of adjunctive anticoagulant therapy with enoxaparin for the duration of the index hospitalization was superior to the standard two-day UFH regimen in patients with STEMI treated with fibrinolytic therapy. 6 However, little information is available regarding the efficacy and safety of enoxaparin across a range of available lytics agents. 7, 8 In the ExTRACT-TIMI 25 trial, alteplase, tenecteplase, reteplase, or SK was administered to STEMI patients at the discretion of the treating physician, and 30-day outcomes were evaluated. We report a pre-specified subgroup analysis conducted to determine the efficacy and safety of the administration of a strategy of enoxaparin compared with UFH stratified by the type of lytic therapy used in the trial.
Methods

Patient population and study protocol
The design of the ExTRACT-TIMI 25 trial has been reported previously. 9 In brief, patients aged 18 years presenting within 6 h of the onset of symptoms of STEMI scheduled to undergo fibrinolysis were treated with a fibrinolytic agent (alteplase, tenecteplase, reteplase, or SK) selected by the treating physician and administered according to the package insert for the treatment of STEMI. Patients were to receive aspirin (recommended dose of 150-325 mg in a nonenteric formulation orally or 500 mg intravenously on the first day and 75-325 mg daily thereafter for at least 30 days). Clopidogrel could be added to aspirin at the treating physician's discretion. Patients were randomly assigned in a 1:1 ratio to receive enoxaparin or UFH in a double-blinded fashion with a double-dummy design. UFH or matching placebo was given as an i.v. Total n represents the number of patients with available information for the baseline characteristic. Otherwise, the number of patients included in each fibrinolytic cohort should be considered. ACE, angiotensin-converting enzyme. The TIMI risk score was calculated as previously described. 9 Higher scores indicate higher risk.
bolus of 60 U kg 21 (maximum 4000 U) followed by a continuous infusion at 12 U kg 21 h 21 (maximum 1000 U h
21
) initiated within 15 min after the bolus and continued for at least 48 h. The dose of UFH was adjusted to maintain an activated partial thromboplastin time of 1.5-2.0 times the control value. The enoxaparin dosing regimen was adjusted according to the patient's age and renal function, as described elsewhere. 9 The subcutaneous enoxaparin regimen was continued until hospital discharge or for a maximum of eight days.
Patients were monitored for clinical outcomes and adverse events either in person or by telephone during their hospitalization and through day 30.
Outcomes
The primary efficacy end point of the trial and of this analysis was the composite of all-cause mortality or nonfatal recurrent MI in the first 30 days after randomization. The main, secondary end point was the composite of death from any cause, nonfatal reinfarction, or recurrent myocardial ischemia leading to urgent revascularization in the first 30 days. The primary safety end point was TIMI major bleeding. All-cause mortality, nonfatal reinfarction, or a nonfatal episode of major bleeding was a pre-specified net clinical benefit end point. The definition of the end points has been described previously. 9 
Statistical analysis
The population used for the statistical analysis included patients randomized in the trial and treated with fibrinolytic therapy. The comparison of baseline characteristics between patients treated with fibrin-specific lytics vs. SK was performed using t-tests or Wilcoxon rank sum tests for normally or non-normally distributed continuous variables, respectively, and x 2 tests were applied for categorical variables. All efficacy comparisons were analysed according to the intention-to-treat principle. The x 2 test was used to compare the primary and secondary end points in the UFH and enoxaparin groups stratified by each of the four fibrinolytic agents used in the trial. All safety analyses were performed according to the treatment actually received by the patient. Multivariable analyses for the evaluation of efficacy, safety, and composite end points stratified by lytic type included components of the TIMI risk score such as age, weight, anterior location of the MI, previous angina, history of hypertension or diabetes, time to fibrinolysis and systolic blood pressure, heart rate, and Killip class upon admission. Adjustment was also performed for the different regions of the world as local practice might influence outcomes. The five regions selected for this adjustment were (i) North America, (ii) South America, (iii) Australia, Asia, and Africa, (iv) Western Europe, and (v) Eastern Europe (reference). A univariate regression model was performed for the assessment of the interaction between randomized therapy and fibrinolytic treatment. A P-value of ,0.05 was the threshold for nominal significance for all end points.
Analyses were done with Stata/SE version 9.2 (StataCorp). 10 
Results
A total of 20 479 patients with STEMI were included in the intention-to-treat population. Overall, 16 283 (79.7%) patients were treated with fibrin-specific lytics and 4139 (20.3%) received SK. A total of 57 patients in the intention-to-treat population were not treated with fibrinolytic therapy and therefore were not considered in this analysis. Of the patients who received fibrin-specific agents, 11 175 (68.6%) patients were treated with alteplase, 3986 (24.5%) with tenecteplase, and the remainder 1122 (6.9%) were treated with reteplase. Baseline characteristics stratified by the category of lytic are shown in Table 1 . Patients who received SK were older and had a higher prevalence of diabetes. In-hospital medical therapy was comparable in both cohorts. Patients in both groups were treated according to contemporary guidelines and received aspirin (95.2%), beta-blockers (85.8%) and inhibitors of the renin-angiotensin system (79.7%).
Efficacy outcomes stratified by lytic
The rate of the primary efficacy end point (death or nonfatal MI) in the fibrin-specific cohort at 30 days was 12.0% in patients treated with UFH compared with 9.8% in the enoxaparin group [odds ratio adj (OR adj ) 0.78; 95% CI 0.70-0.87; P , 0.001; Table 2 and Figure 1] . A strategy of enoxaparin also significantly reduced the rates of recurrent MI in the fibrin-specific cohort (4.6 vs. 3.1%; OR adj 0.68; 95% CI 0.57-0.80; P , 0.001). The benefit of enoxaparin strategy observed in the primary end point and its components for the fibrin-specific cohort was also present for the alteplase, tenecteplase, and reteplase cohorts analysed separately ( Table 3) . In patients who received SK, the primary end point occurred in 11.8% of those receiving UFH and 10.2% of those treated with enoxaparin (OR adj 0.83; 95% CI 0.66-1.04; P ¼ 0.10). A significant 31% reduction in the adjusted OR of nonfatal reinfarction was observed in the SK cohort treated with enoxaparin (3.8 vs. 2.7%; P ¼ 0.05) ( Table 2) . A test for interaction between antithrombin group and fibrinspecific vs. SK cohorts was non-significant for the composite primary end point (P ¼ 0.58; Figure 1) . Analysis of the time course of the treatment effect of enoxaparin shows that the rates of the primary end point death or recurrent MI were significantly reduced in the fibrin-specific cohort on the first day of therapy (OR adj 0.81; 95% CI 0.67-0.98; P ¼ 0.03; Figure 2A ). In the SK cohort, the point estimate favoured the enoxaparin strategy by day 3, and increased progressively during the course of therapy ( Figure 2B) .
A strategy of enoxaparin also significantly reduced the secondary end point of all-cause mortality, nonfatal MI, or urgent revascularization in both lytic cohorts compared with UFH (Table 2 and Figure 3) . Interaction tests between anticoagulant groups and fibrin-specific vs. SK cohorts were non-significant for the secondary end point (P ¼ 0.60) (Figure 3) . Episodes of recurrent myocardial ischemia leading to urgent target vessel revascularization were significantly decreased by enoxaparin both in patients who received fibrin-specific lytics (2.7 vs. 2.1%, OR adj 0.76; 95% CI 0.61-0.93; P ¼ 0.009) as well as SK (3.2 vs. 2.2%, OR adj 0.62; 95% CI 0.41-0.92; P ¼ 0.02) ( Table 2 ). The benefits of the enoxaparin strategy for these end points were also present when alteplase, tenecteplase, and reteplase cohorts were analysed separately ( Table 3) .
Safety outcomes stratified by lytic
The rates of TIMI major bleeding (including intracranial hemorrhage) at 30 days in patients treated with fibrinspecific lytics were significantly elevated from 1.2% in the UFH group to 2.0% in the enoxaparin strategy group (OR adj 1.89; 95% CI 1.43-2.51; P , 0.001) ( Table 4) . Similarly elevated rates of major bleeding without intracranial haemorrhage were seen in patients treated with a strategy of enoxaparin (0.6 vs. 1.1%; OR adj 2.23; 95% CI 1.51-3.30; P , 0.001). Within fibrin-specific-treated patients, intracranial haemorrhage occurred in 0.6% in the UFH group and 0.9% in the enoxaparin group (OR adj 1.55; 95% CI 1.03-2.33; P ¼ 0.04) ( Table 4) .
In the SK cohort, major bleeding including intracranial haemorrhage occurred in 2.0% of the patients receiving UFH and 2.4% of those treated with enoxaparin (OR adj 1.38 95% CI 0.88-2.17; P ¼ 0.16) ( Table 4 ). The rates of major bleeding without intracranial haemorrhage were 1.3% in the UFH group and 1.9% in the enoxaparin group (OR adj Figure 1 Adjusted odds ratio for the primary end point at 30 days in the various fibrinolytic groups. The primary efficacy end point in the ExTRACT-TIMI 25 trial was a composite of all-cause mortality or nonfatal recurrent myocardial infarction in the first 30 days. For each subgroup, the filled square is proportional to the number of patients, and represents the point estimate of the treatment effect; the horizontal lines represent the 95% confidence intervals. Although some variation was observed in the estimate of treatment with enoxaparin on the primary end point across the fibrinolytic subgroups, P-value for interaction between fibrin-specific and SK was non-significant (P ¼ 0.58). A benefit of the strategy of enoxaparin was present for all fibrinolytic agents used in the trial. UFH, unfractionated heparin; ENOX, enoxaparin; NNT, number of patients needed to treat to prevent one event.
1.74; 95% CI 1.02-2.97; P ¼ 0.04). The incidence of intracranial haemorrhage in the SK cohort was 0.7% for patients treated with UFH and 0.5% for those who received the enoxaparin strategy (OR adj 0.75; 95% CI 0.31-1.80; P ¼ 0.52) ( Table 4) . Interaction tests for major bleeding risk and intracranial haemorrhage were non-significant between fibrinspecific vs. SK cohorts and anticoagulant assigned in the trial (P ¼ 0.20 and 0.12, respectively).
Net clinical benefit
The rates of the pre-specified net clinical benefit end point (all-cause mortality, nonfatal reinfarction, and major bleeding) in the fibrin-specific cohort were 12.7 and 10.8% for patients treated with UFH and enoxaparin, respectively (OR adj 0.82; 95% CI 0.74-0.91; P , 0.001). Although not statistically significant, net clinical benefit in the SK cohort was directionally in favour of enoxaparin (11.8%) vs. UFH (13.0%) (OR adj 0.89; 95% CI 0.72-1.10; P ¼ 0.29). Interaction test between antithrombin groups and fibrinspecific vs. SK cohorts was non-significant for the net clinical benefit comparison (P ¼ 0.53).
Discussion
Our findings demonstrate the superiority of anticoagulant therapy with a strategy of enoxaparin throughout the index hospitalization over the standard strategy of 2 days of UFH in STEMI patients undergoing pharmacological re-perfusion across the spectrum of four lytics available around the world that were used in ExTRACT-TIMI 25. A significant reduction in the primary end point of all-cause mortality, or nonfatal recurrent MI as well as the secondary end point of death, nonfatal reinfarction, or urgent revascularization were observed in patients randomized to enoxaparin in both the fibrin-specific lytic cohort and each of the fibrinspecific lytics analysed independently. Reductions in the primary and secondary efficacy end points were also seen with enoxaparin in the SK cohort, although the magnitude of the benefit was somewhat smaller than in the fibrinspecific cohort. The benefits of the enoxaparin strategy over UFH for the prevention of death or nonfatal MI translate into a number of patients who need to be treated (NNT) to prevent one event of 48 and 67 for the fibrinspecific and SK cohorts, respectively. To prevent the secondary end point of death, nonfatal recurrent MI, or urgent revascularization, the NNTs are 34 for patients receiving fibrin-specific lytics and 43 for those treated with SK. The advantage of enoxaparin over UFH may be related to both a direct anticoagulant benefit as suggested by a significant decrease in the primary end point after 24 h of treatment and to the longer duration of therapy as seen by the incremental advantage after UFH is stopped.
Importantly, the use of enoxaparin was associated with a 32 and 31% reduction in the OR of nonfatal recurrent infarction in the fibrin-specific and SK cohorts, respectively. The rates of myocardial ischemia leading to urgent revascularization were reduced by 24% in the fibrin-specific cohort and 38% in the SK cohort. The observation of reduced reinfarction and recurrent ischemia associated with enoxaparin strategy assumes great relevance, as these complications are associated with increased mortality rates in patients treated with fibrinolysis. Results are expressed as numbers of events (%). OR, odds ratio; CI, confidence interval; UFH, unfractionated heparin; ENOX,enoxaparin; MI, myocardial infarction. Results are adjusted for the TIMI risk score and region.
Major bleeding rates were significantly higher in the enoxaparin group of both fibrin-specific and SK cohorts. While the concomitant use of enoxaparin with fibrin-specific agents increased ICH, the opposite effect was seen in patients treated with SK. Caution should be used during the interpretation of subgroup analysis especially when interaction tests are negative. Despite the increase in bleeding, adjustments of the enoxaparin dose in the elderly and patients with renal failure might have contributed to prevent the highly elevated haemorrhagic rates observed in previous trials in which antiplatelet 11 and antithrombin 12, 13 agents were combined with fibrinolytic agents, particularly SK.
The evaluation of net clinical benefit end points is of particular importance as it integrates efficacy and safety outcomes. Despite the significant increase observed in Figure 3 Adjusted odds ratio for the secondary end point at 30 days in the various fibrinolytic groups. The secondary efficacy end point in the ExTRACT-TIMI 25 trial was a composite of all-cause mortality, nonfatal reinfarction, or myocardial ischemia leading to target vessel revascularization in the first 30 days. For each subgroup, the filled square is proportional to the number of patients, and represents the point estimate of the treatment effect; the horizontal lines represent the 95% confidence intervals. Although a small variation was observed in the estimate of treatment with enoxaparin on the secondary end point across the fibrinolytic subgroups, a significant benefit was observed for fibrinolytics tested in the trial. P-value in tests for interaction between fibrin-specific and SK was non-significant (P ¼ 0.60). UFH, unfractionated heparin; ENOX, enoxaparin; NNT, number of patients needed to treat to prevent one event. Figure 2 Adjusted odds ratio for the primary end point by day of treatment in the fibrin-specific and streptokinase cohorts. The primary efficacy end point in ExTRACT-TIMI 25 was a composite of all-cause mortality or nonfatal recurrent myocardial infarction. For each subgroup, the filled square is proportional to the number of patients, and represents the point estimate of the treatment effect; the horizontal lines represent the 95% confidence intervals. (A) In the fibrinspecific cohort, a significant reduction in the primary end point was seen in patients treated with enoxaparin by day 1. (B) In patients receiving streptokinase, the point estimate favoured enoxaparin by day 3 and the magnitude of the treatment effect increased progressively during the course of treatment. UFH, unfractionated heparin; ENOX, enoxaparin. major bleeding, net clinical benefit analyses favoured the enoxaparin strategy in both fibrin-specific and SK cohorts. These findings highlight the importance of concomitant antithrombin therapy in fibrinolysis with both fibrin-specific agents and SK, as previously demonstrated. 14 The results presented are anticipated to impact the treatment of STEMI. From our data, we expect that for every 1000 patients treated with fibrin-specific lytics and enoxaparin, a total of 29 fewer deaths, recurrent MIs, or urgent revascularization will occur. When SK is the lytic chosen, 23 secondary end points will be prevented. Many physicians perceive that fibrin-specific lytics are more efficient than SK. In this case, adjunctive antithrombotic therapy with enoxaparin becomes an attractive therapy as it clearly reduces nonfatal recurrent MI and urgent revascularization in fibrin-specific-treated patients. On the other hand, SK is the most frequently prescribed fibrinolytic agent around the world, 15 particularly in developing countries as physicians have accumulated vast experience with this compound that is the least expensive among the available lytics. 16 A reduction in the composite secondary end point of death, recurrent MI, and urgent revascularization in patients undergoing fibrinolysis with SK favourably impacts the outcomes of SK-treated patients. Because more patients are treated with SK around the world, it is anticipated that the global impact of the combination with enoxaparin may actually be greater for SK than fibrin-specific lytics.
Limitations
Potential limitations of this ExTRACT-TIMI 25 subanalysis deserve consideration. One important confounding factor is the non-randomized nature of the fibrinolytic therapy administered to the patient. An analysis including prognostic and country variables was performed to adjust for such potential confounders. Another limitation of this study is that it was not powered to detect differences between subgroups. Therefore, a direct comparison of treatment effect between different fibrinolytics cohorts was not possible. Interaction tests, however, suggested similar benefits from all lytic subgroups.
Clinical implications
In patients with STEMI undergoing pharmacological reperfusion, recurrent MI, and ischaemic events leading to urgent revascularization were significantly reduced with the enoxaparin strategy compared with UFH as adjunctive anticoagulant therapy with both fibrin-specific lytics and SK. Although major bleeding was higher in both lytic cohorts, all composite net clinical benefit end points favoured enoxaparin regardless of the lytic prescribed. These findings strongly suggest that a strategy of enoxaparin is preferred over UFH to support fibrinolysis for STEMI across the range of lytics in common clinical use.
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